HEALTH: Summary of Oct 23, 2026

By · Published on

Illustration representing health and medical care
AI-generated illustration; does not depict the actual event.

Friday’s health summary covers the widening Ebola outbreak in Congo and its toll on mental health, signs of bird flu infection in polar bears in Greenland, a cheaper malaria vaccine for children, a drug combination that cleared visible cancer in one patient, and a study describing the typical human genome.

Ebola outbreak in Congo spreads further as families face a mental health toll

The Ebola outbreak that began in Congo in May has now infected more than 9,700 people, and almost half of them have died, making it the deadliest in the country’s history. It is caused by the rare Bundibugyo virus, for which no vaccine or treatment has been approved. Nigeria this week became the fourth country outside Congo to record a case, in a woman who had returned from Uganda. Kenya has recorded nine cases, and France treated an infected doctor in June.

Health workers in eastern Congo say the psychological damage is spreading too. A woman being treated at a mental health centre in Bunia, who lost five relatives, said neighbours were too frightened to come near her family. Mirella Riccardi, a mental health and psychosocial support specialist with Médecins Sans Frontières, said war and displacement had already left communities fragile. Jean Kaseya, head of the Africa Centres for Disease Control and Prevention, called for faster and better coordinated action across borders.

The Bundibugyo virus takes its name from the district in western Uganda where it was first identified in 2007, and it caused further outbreaks in 2012 and this year. Bleeding, common with other forms of Ebola, has appeared in only about one in ten patients in the current epidemic, which makes the disease harder to recognise and delays isolation. African officials have also raised concerns that 700 million dollars in Ebola aid cannot be accounted for.


Antibodies against avian influenza found in Greenland’s polar bears

Scientists have found evidence of past bird flu infections in polar bears in eastern Greenland for the first time, in a study published in the journal Emerging Infectious Diseases. Researchers tested 109 blood samples supplied by Inuit hunters near Ittoqqortoormiit between 2016 and 2025. None showed antibodies to influenza A until 2024, when three of 14 bears tested positive. In 2025 the figure rose to six of 14, and four bears carried antibodies specific to highly pathogenic strains.

Kayla Buhler, the lead author, who works at Cornell University and the University of Inland Norway, said the bears had cleared the infections and appeared healthy, and hunters had seen no sick animals. She said melting sea ice was pushing bears on to land, where they increasingly raid bird colonies and eat eggs, exposing them to new pathogens. Migratory routes from Europe and the Americas meet in Greenland, which she said makes closer monitoring there valuable.

Polar bears are the largest land carnivores and depend on sea ice to hunt seals, their main prey. The International Union for Conservation of Nature lists the species as vulnerable, with an estimated 22,000 to 31,000 animals left in the wild, and climate change ranks among its biggest threats. Dead polar bears carrying bird flu have previously been found in Alaska and Svalbard, where a young bear died this year after eating an infected walrus.


Gavi and Unicef agree a 40% cut in the price of a malaria vaccine

Unicef and the Geneva-based vaccine alliance Gavi said on Thursday that they had agreed to reduce the price of the Mosquirix malaria vaccine by about 40%, to 5.50 euros a dose. The deal, carried out by Unicef with financial backing from Gavi, is expected to save about 50 million dollars between 2027 and 2029. The two organisations said the lower price should apply from early 2027, freeing money for other childhood immunisation programmes.

The cut depends on moving production from the drugmaker GSK to India’s Bharat Biotech, which is due to take over manufacturing fully by 2028, while GSK continues to supply the ingredient that boosts the immune response. Several regulatory and manufacturing steps must be completed before Unicef starts buying doses, including approval by the World Health Organization of a new factory. Last year the two groups secured a 25% cut for a second malaria vaccine.

Mosquirix, also known as RTS,S, was created by GSK scientists in Belgium in the late 1980s and developed with support from the non-profit PATH and the Gates Foundation. It became the world’s first licensed malaria vaccine and the first approved against any human parasitic disease. Children need at least three doses by the age of two, and the vaccine reduces hospital admissions for severe malaria by about 30%. The other approved malaria vaccine is R21.


Drug combination clears signs of metastatic breast cancer in Kansas City patient

A 57-year-old woman in Kansas City, Missouri, who was told five years ago that she might have only two to five years to live, now has a scan report stating there is no evidence of metastatic breast cancer. Lori Anderson was diagnosed with triple-negative breast cancer in 2021 and treated with chemotherapy, surgery, radiation and immunotherapy. By early 2023 the disease had spread to her skin, and by June her treatment was no longer keeping it under control.

Doctors at Saint Luke’s Hospital decided to pair the immunotherapy drug pembrolizumab, sold as Keytruda, with sacituzumab govitecan, sold as Trodelvy, a drug that carries chemotherapy directly to cancer cells. Little published evidence on the combination existed at the time. Timothy Pluard, who led her care, said it was clear within weeks that it was working. Her tumour markers later became undetectable, and a scan in September found no sign of spread.

Triple-negative breast cancer lacks the three receptors targeted by common treatments, which means hormone therapies do not work against it. It accounts for 15% to 20% of breast cancers and is considered the hardest type to treat, with a high risk of relapse in the first three to five years. The combination Anderson received was later tested in clinical studies and approved by American regulators for certain patients with advanced disease.


Study of nearly a million genomes describes the average human genome

Researchers at the University of Exeter have described what a typical human genome looks like, using whole-genome data from almost a million people in two large biobanks. Their study, published in Genome Medicine, found that each person differs from the reference sequence at roughly five million points, most of them harmless. Everyone carries one to three rare variants known to cause serious genetic disease, usually as healthy carriers, plus about 50 whose effects remain unclear.

Using polygenic scores for 28 common conditions, including diabetes and heart disease, the team found that the average person would rank as high genetic risk for about three. Professor Caroline Wright, the senior author, said variation was the norm and that results must be read alongside symptoms, family history and other factors. Each person is born with about 61 new mutations, mostly from the father, and the number rises by about 1.2 for each year of the father’s age.

The data came from UK Biobank and the American All of Us programme. UK Biobank, based in Stockport, holds samples and health records from half a million volunteers aged 40 to 69, recruited between 2006 and 2010, who agreed to be followed for at least 30 years. The researchers noted that participants are mostly of Western European origin and said more diverse data was needed, as people of African ancestry carried about a million more variants on average.

In this topic